Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Bevacizumab and Vorinostat for Recurrent WHO Grade IV Malignant Glioma Patients

NCT01738646 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT01738646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01738646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Bevacizumab and Vorinostat for Recurrent WHO Grade IV Malignant Glioma Patients
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2013
Completion date
February 29, 2016
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult brain tumor, malignant glioma, recurrent glioblastoma multiforme